Navigation Links
Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
Date:11/14/2007

CORAL GABLES, Fla., Nov. 14 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the quarter ended September 30, 2007.

Third Quarter 2007 Results

For the quarter ended September 30, 2007, the Company reported a net loss of $734,347 or $0.06 loss per basic and diluted share, compared to a net loss of $1,321,388, or $0.19 loss per basic and diluted share for the same period in 2006. Third quarter 2007 results were impacted by non-cash charges relating to stock-based compensation in the amount of $94,482, compared to $828,818 in the same period in 2006. For the nine months ended September 30, 2007, the Company reported a net loss of $3,194,555, or $0.26 loss per basic and diluted share, compared to a net loss of $1,988,213, or $0.29 loss per basic and diluted share for the same period in 2006. Results for the first nine months of 2007 were impacted by non-cash charges relating to stock-based compensation in the amount of $477,083, compared to $1,069,943 in the same period in 2006.

Research and development expenses for the third quarter of 2007 were $503,348, an increase of 113.8% compared to $235,467 in the third quarter of 2006. These include non-cash stock-based compensation of $75,997 and $88,993, respectively. Research and development expenses for the nine months ended September 30, 2007 were $2,268,648, an increase of 239.5% compared to $668,231 for the first nine months of 2006. These include non-cash stock-based compensation of $315,710 and $302,368, respectively.

General and administrative expenses for the third quarter of 2007 totaled $447,078, a decrease of 59.6% compared to $1,106,752 in the third quarter of 2006. These include non-cash stock-based compensation of $18,485 and $739,825, respectively. General and administrative expenses for the first nine months of 2007 totaled $1,615,912, an increase of 19.8% compared to $1,348,945 for the first nine months of 2006. These include non-cash stock-based compensation of $161,373 and $767,575, respectively.

As a development stage pharmaceutical company, Catalyst has no revenues to-date.

At September 30, 2007, the Company had cash and cash equivalents totaling $16.9 million and no long-term debt. The Company believes that its existing cash and cash equivalents will be sufficient to meet the Company's projected operating requirements through the end of 2008.

Commenting on today's news, Patrick J. McEnany, Catalyst's Chief Executive Officer, noted, "We continue to move ahead with our clinical developments program for CPP-109. In particular, we have initiated our first U.S. Phase II clinical trial which will evaluate CPP-109 as a treatment for cocaine addiction. We also expect to initiate our U.S. Phase II clinical trial evaluating CPP-109 as a treatment for methamphetamine addiction in the first quarter of 2008."

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to http://www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including our ability to successfully complete the clinical trials required for us to file a new drug application for CPP-109, our ability to complete such trials on a timely basis within the budgets we establish for such trials, our ability to protect our intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2006 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS (unaudited)

For the Three Months For the Nine Months

Ended Ended

September 30, September 30,

2007 2006 2007 2006

Revenues $- $- $- $-

Operating costs and expenses:

Research and

development 503,348 235,467 2,268,648 668,231

General and

administrative 447,078 1,106,752 1,615,912 1,348,945

Total operating costs

and expenses 950,426 1,342,219 3,884,560 2,017,176

Loss from operations (950,426) (1,342,219) (3,884,560) (2,017,176)

Interest income 216,079 20,831 690,005 28,963

Loss before income

taxes (734,347) (1,321,388) (3,194,555) (1,988,213)

Provision for

income taxes - - - -

Net loss $(734,347) $(1,321,388) $(3,194,555) $(1,988,213)

Loss per share - basic

and diluted $(0.06) $(0.19) $(0.26) $(0.29)

Weighted average shares

outstanding - basic

and diluted 12,527,564 7,020,508 12,524,678 6,932,332

CATALYST PHARMACEUTICAL PARTNERS, INC.

(a development stage company)

CONDENSED BALANCE SHEETS

September 30, December 31,

2007 2006

(unaudited)

ASSETS

Current Assets:

Cash and cash equivalents $16,886,194 $20,434,702

Interest receivable 65,559 85,787

Prepaid expenses 495,831 67,333

Total current assets 17,447,584 20,587,822

Property and equipment, net 125,517 20,157

Other assets 20,388 11,500

Total assets $17,593,489 $20,619,479

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable $ 229,478 $448,072

Accrued expenses 175,576 324,774

Total current liabilities 405,054 772,846

Total stockholders' equity 17,188,435 19,846,633

Total liabilities and stockholders' equity $17,593,489 $20,619,479


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: